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A B S T R A C T
Growing evidence indicates that protein synthesis is deregulated in cancer onset and progression and targeting
this process might be a selective way to combat cancers. While harmine is known to inhibit DYRK1A and
intercalate into the DNA, tri-substitution was shown previously to modify its activity profile in favor of protein
synthesis inhibition. In this study, we thus evaluated the optimized derivative CM16 in vitro anti-cancer effects
unfolding its protein synthesis inhibition activity. Indeed, the growth inhibitory profile of CM16 in the NCI 60-
cancer-cell-line-panel correlated with those of other compounds described as protein synthesis inhibitors.
Accordingly, CM16 decreased in a time- and concentration-dependent manner the translation of neosynthesized
proteins in vitro while it did not affect mRNA transcription. CM16 rapidly penetrated into the cell in the
perinuclear region of the endoplasmic reticulum where it appears to target translation initiation as highlighted
by ribosomal disorganization. More precisely, we found that the mRNA expression levels of the initiation factors
EIF1AX, EIF3E and EIF3H differ when comparing resistant or sensitive cell models to CM16. Additionally,
CM16 induced eIF2α phosphorylation. Those effects could explain, at least partly, the CM16 cytostatic anti-
cancer effects observed in vitro while neither cell cycle arrest nor DNA intercalation could be demonstrated.
Therefore, targeting protein synthesis initiation with CM16 could represent a new promising alternative to
current cancer therapies due to the specific alterations of the translation machinery in cancer cells as recently
evidenced with respect to EIF1AX and eIF3 complex, the potential targets identified in this present study.
1. Introduction
Among various processes that enable the continuous growth,
multiplication and dissemination of malignant cells (Hanahan and
Weinberg, 2011), protein synthesis plays an important role in the onset
and progression of cancer. Growing evidence indicates that targeting
mRNA translation as a cancer therapy has the potential of selectively
eradicating cancerous cells (Bhat et al., 2015; Nasr and Pelletier, 2012;
Spilka et al., 2013). In eukaryotic cells, mRNA translation occurs in
four stages: initiation, elongation, termination and ribosome recycling.
Among these, initiation is believed to be pivotal in the regulation of
translation (Sonenberg and Hinnebusch, 2009), and is often altered in
cancer through dysregulation of expression and/or phosphorylation
status of translation initiation proteins, including eIF2α, eukaryotic
translation initiation factor 3 (eIF3) and members of the eukaryotic
translation initiation factor 4F complex (eIF4F) (Bhat et al., 2015;
Blagden and Willis, 2011; Silvera et al., 2010). Translational control
contributes to maintain several oncogenic programs (Silvera et al.,
2010) and is reciprocally affected by oncogenic signaling pathways,
which include MAPK and PI3K-AKT-mTOR (Bader et al., 2005;
Topisirovic and Sonenberg, 2011). In response to energy and nutrient
demand, mTOR is activated by the PI3K signaling cascade and
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promotes the assembly of the eIF4F complex resulting in the cap-
dependent translation (Hay and Sonenberg, 2004; Ma and Blenis,
2009). Thus, the elevated activity of the translation machinery compo-
nents and regulators makes them potential selective therapeutic targets
to combat cancer cells (Bhat et al., 2015; Blagden and Willis, 2011;
Malina et al., 2012).
Harmine, a natural β-carboline, is known to exert anticancer
properties through i) the inhibition of DYRK1A (Göckler et al., 2009;
Seifert et al., 2008), a protein kinase linked to tumorigenesis (Abbassi
et al., 2015; Laguna et al., 2008; Pozo et al., 2013) and ii) DNA
intercalating properties (Nafisi et al., 2010; Sarkar et al., 2014).
Although displaying more potent growth inhibition than harmine itself,
2,7,9-tri-substituted β-carbolines exhibit no effect on DYRK1A, but
instead were found to be possible protein synthesis inhibitors
(Frédérick et al., 2012). Optimization of their pharmacological and
physico-chemical properties led to the identification of CM16 as the
lead compound, which to the best of our knowledge is the first
harmine-derived beta-carboline (Meinguet et al., 2015) to be studied
for its potential as protein synthesis inhibitor of cancer cells. The
present study examines the anti-cancer properties of CM16 at the
cellular level and on protein synthesis in three cancer cell models of
different histological origins, i.e. the melanoma SKMEL-28, the glioma
Hs683 and the breast cancer MDA-MB-231 models. We discovered
EIF1AX and eIF3 complex members, recently identified as potential
cancer targets, as possible regulators of cancer cell sensitivity to CM16.
2. Materials and methods
2.1. Cell lines and compounds
The human cancer cell lines, oligodendroglioma Hs683 (ATCC code
HTB-138), melanoma SKMEL-28 (ATCC code HTB-72) and breast
adenocarcinoma MDA-MB-231 (ATCC HTB26), as well as the normal
human cell lines, skin fibroblasts NHDF (Lonza CC-2509), and lung
fibroblasts NHLF (Lonza CC-2512) were selected for the current
investigation. Cells were cultivated at 37 °C with 5% CO2 in RPMI
culture medium supplemented with 10% FBS, 200U penicillin-strep-
tomycin, 0.1 mg/ml gentamicin and 4 mM L-glutamine, or fibroblast
medium FBM supplemented with 2% fetal bovine serum, 0.1% insulin,
rhFGF-B and gentamicin. MDA-MB-231 cells were cultured in DMEM
supplemented with 10% FBS, 100 U/ml penicillin/streptomycin, and
2 mM L-glutamine at 37 °C and 5% CO2. CM16 was synthetized as
previously described (Meinguet et al., 2015).
2.2. MTT colorimetric assay
Cells were first grown in 96 well plates for 24 h and then treated
with CM16 at different concentrations up to 100 µM or left untreated
for 72 h. Viability was estimated by means of the MTT - 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (Sigma,
Bornem, Belgium) mitochondrial reduction into formazan as pre-
viously described (Mosmann, 1983). Two experiments were performed
in non-cancerous cell lines (NHDF and NHLF) and three in cancerous
cell lines (Hs683, SKMEL-28 and MDA-MB-231), each in sextuplicate.
2.3. Quantitative videomicroscopy
Computer-assisted phase contrast microscopy was performed as
previously described (Debeir et al., 2008). Briefly, Hs683, SKMEL-28
or MDA-MB-231 cells were seeded in 25 cm2 culture flasks and left
untreated or treated with CM16 at their GI50 concentrations deter-
mined with the MTT colorimetric assay or at the concentration 10
times higher. Pictures of one field were taken every four min during a
72 h period and further compiled into a short movie (Debeir et al.,
2008). Quantitatively, global growth ratio was determined based on cell
counting of pictures corresponding to 24 h, 48 h and 72 h in compar-
ison to 0 h. Experiments were performed once in triplicates.
2.4. Fluorescence assays
2.4.1. CM16 cell penetration and distribution analysis
The fluorescence properties of CM16 were first determined in a
phosphate buffer at pH 7.4 as ex/em: 330/439 nm. To qualitatively
analyze the CM16 cell penetration and distribution, tumor cells
(Hs683, SKMEL-28 and MDA-MB-231) were seeded on glass cover-
slips in cell culture plates and, after attachment, treated with 5 µM
CM16 or left untreated. For imaging of the living cells, medium was
removed and PBS was added. Coverslips were rapidly transferred to a
slide and images were captured with the Imager M2 fluorescence
microscope (Carl Zeiss, Zaventem, Belgium) coupled with the AxioCam
ICm1 and AxioImager software (Carl Zeiss, Zaventem, Belgium). The
experiment was conducted twice in duplicate and three images per
condition were taken.
2.4.2. Ribosome fluorescent staining
Endoplasmic reticulum (ER) staining of cells was performed with
glibenclamide ER-tracker red dye (Molecular Probes - Life
Technologies, Merelbeke, Belgium) by fluorescence microscopy. Cells
were seeded on coverslips in cell culture plates and left untreated or
treated with CM16 after attachment (at least 24 h). Following treat-
ment, the dye solution (1 µM in PBS) was incubated with the samples
for 30 min at 37 °C. The staining solution was replaced with cell culture
medium and sample-containing coverslips were transferred to micro-
scope slides. The imaging of living cells was performed similarly to
description above (item a) with fluorescence microscope (Carl Zeiss,
Zaventem, Belgium). Experiments were conducted once or twice,
depending on the cell line, in duplicate and five images per condition
were taken.
2.5. Protein neosynthesis evaluation
2.5.1. Fluorescence method
To evaluate the effects of CM16 on neosynthesized proteins the
Click-iT AHA alexa fluor 488 kit (Invitrogen, Life Technologies,
Merelbeke, Belgium) was used. A methionine analog L-azidohomoala-
nine is incorporated in newly synthesized proteins and reacts with an
alkyne coupled to alexa 488 fluorescent dye allowing measurement (ex/
em: 495/520 nm). Hs683, SKMEL-28 and NHDF cells were seeded in
96 wells plates and left untreated or treated with CM16 or positive
control, i.e. cycloheximide (Santa Cruz Biotech., Heidelberg, Germany).
The treatment was followed by the addition of L-azidohomoalanine (1/
1000) for four h. After fixation with formaldehyde, the neosynthesized
proteins were stained according to the manufacturer's recommenda-
tions. Normalization according to cell number was carried out as
described in the user manual with Hoescht counterstaining. The
fluorescent signal was measured in a microplate reader (SynergyMX
Biotek, Winooski, USA: ex/em: 350/460 nm). Experiments were
performed each in sextuplicate.
2.5.2. 35S Methionine incorporation
MDA-MB-231 or NHDF cells were seeded (50,000 cells per well in
a 12 well plate format) one day prior to the labeling experiment. On the
day of the experiment, cells were incubated with CM16 at the indicated
concentrations for a total of 1 h and 20 min. During the last 20 min,
[35S]-methionine/cysteine (150–200 µCi/ml) (Perkin Elmer, Waltham,
MA) was added to the cells. At the end of the incubation, cells were
washed twice with ice-cold PBS and labeling reactions were terminated
through the addition of RIPA buffer. Newly synthesized radiolabeled
proteins were precipitated on 3 MM Whatman paper (pre-blocked with
0.1% L-methionine) using trichloroacetic acid (TCA) and washed twice
with 5% TCA, followed by two washes of ethanol. Samples were then
dried and quantitated using scintillation counting. CPMs were normal-
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ized to total protein, which was determined using the DC Assay (Bio-
rad). Experimental results represent three biological replicates, each
performed in technical duplicate.
2.6. Investigation of the translation initiation: ribosome and
polysome organization study
Ribosomes and polysomes were separated through ultracentrifuga-
tion in sucrose gradient, as described in Cencic et al. (2007). Briefly,
Hs683, SKMEL-28, NHDF, NHLF cells were seeded in cell culture
flasks and left untreated (negative control) or treated with puromycin
or CM16. Cells were then scraped and collected in a PBS buffer
containing 100 µg/ml cycloheximide and centrifuged (400×g, 4 °C,
10 min). Pellets were resuspended in a hypotonic lysis buffer (5 mM
Tris pH 7,5; 2,5 mM MgCl2; 1,5 mM KCl), supplemented with cyclo-
heximide 100 μg/ml, DTT 2 mM, 5 μL RNasin Ribonuclease Inhibitor
(Promega, Leiden, Netherlands), 10 μL of 10% Triton X-100 and 10 μL
of 10% sodium deoxycholate. Samples were centrifuged (16100 rcf,
2 min, 4 °C) and loaded onto a 10 – 50% sucrose gradient and
centrifuged for 2 h at 156,213×g at 4 °C (SW 60 Ti rotor, Beckman,
Ramsey, USA). The obtained gradients were then collected in fractions
through a constant pump flow and absorbance measurement carried
out at 264 nm in a microplate reader (SynergyMX Biotek, Winooski,
USA). Three independent experiments were carried out in the Hs683
and SKMEL-28 cancer cell lines and one experiment in the non-
cancerous non-transformed fibroblasts NHLF and NHDF.
For the polysomes generated using MDA-MB-231 cells, samples
were loaded onto a 10–50% sucrose gradient and centrifuged for 2 h
and 15 min at 217,290×g. The gradients were then fractionated while
reading UV254 absorbance using the Foxy® R1 fraction collector
(Teledyne, ISCO). One experiment (or measurements) was performed.
2.7. Immunodetection
MDA-MB-231 or NHDF cells were treated with the indicated
concentrations of CM16 for 60 min and lysates were collected by
washing the cells with ice cold PBS followed lysis using a buffer
composed of 20 mM HEPES [pH 7.5], 150 mM NaCl, 1% Triton-X100,
10% glycerol, 1 mM EDTA, 10 mM tetrasodium pyrophosphate,
100 mM NaF, 17.5 mM β-glycerophosphate, 1 mM PMSF, 4 mg/ml
aprotinin, and 2 mg/ml pepstatin A. Samples were resolved on a 10%
NuPAGE gel and transferred to a PVDF membrane (BioRad) for
immunoblotting. The following antibodies were used in this study:
eukaryotic elongation factor 2 (eEF2) (#9742, Cell Signaling), pan
eIF2α (#9722, Cell Signaling), phospho-eIF2α (Ser51) (#9721, Cell
Signaling). Two independent experiments were performed.
2.8. NCI data analysis
NCI GI50 profile of CM16 was compared to those of the compounds
in the NCI database with the COMPARE software tool of the NCI (Paull
et al., 1989). Only the compounds displaying a COMPARE correlation
coefficient (CCC) with CM16 above 0.7 were considered in Table 1.
2.9. Statistical analysis
For the transcriptomic comparison, we selected the models with
GI50 > 1 µM or < 0.1 µM as the least versus the most sensitive models
of the NCI 60 cancer cell line panel. A list of potential candidates
regulating or involved in protein synthesis was established based on the
literature and includes the main components of the cap-dependent
translation machinery, as well as kinases and important proteins
involved in the protein synthesis pathways (Table 1 in Carvalho et al.
(2017)). Comparison of the two groups was performed by T-test
comparison of the Z score with the Statistica Software. Z scores are
provided by the NCI and are determined for each probe/cell line pair
by the subtraction from its intensity in the transcriptomic array of the
probe mean across the 60 cell lines, and division by the standard
deviation of the probe (across the 60 cell lines). The z score average was
then calculated as the mean across all probes and probe sets that
passed quality control criteria.
3. Results
3.1. Evaluation of in vitro global growth inhibition by CM16
CM16 (Fig. 1) was evaluated at the National Cancer Institute (NCI
– Bethesda, USA) in the 60 cancer cell line panel. Fig. 2A shows that
the mean 50% growth inhibitory concentration (GI50) obtained by the
NCI is ~0.2 µM and varies from < 0.01 to 4 µM. Of note, 80% of the
cell lines display GI50 close to the mean value, between 0.1 and 0.5 µM
(Fig. 2A). The mean 50% lethal concentration (LC50) in the NCI panel
is 9 µM and ranges from 0.5 to > 100 µM (Fig. 2B). Interestingly, the
response profiles of the 60 cell lines based on the GI50 values differ
from those obtained with the LC50 counterparts. For example, for the
leukemia sub-panel these differential sensitivities are opposite to each
other. These observations indicate that CM16 exerts cytostatic activity
at lower concentrations (close to GI50) through different mechanism(s)
from that associated with its cytotoxic effects at higher concentrations
(close to LC50). Because CM16 does not display specificity towards one
defined cancer type in the NCI panel, we decided to use cancer cell
models of distinct origins, i.e., glioma (Hs683), melanoma (SKMEL-
28) and breast carcinoma (MDA-MB-231), for the current investigation
to limit cell-type specific and context-dependent factors. Moreover,
while keeping the same sensitivity to CM16 effects, these three cell
lines display different sensitivity to apoptosis – SKMEL-28 being
apoptosis-resistant (Mathieu et al., 2009), while Hs683 (Branle et al.,
2002) and MDA-MB-231 (Syed Alwi et al., 2012) are apoptosis-
sensitive. We also included in our assay non-transformed cells, i.e.
dermal and lung fibroblasts. The mean GI50 was about an order of
magnitude lower in cancer cell cultures than in non-cancerous models
(i.e. 0.3 µM versus 3.8 µM respectively; Fig. 3A) indicating moderate
selectivity towards cancer cells. Importantly, our mean GI50 of 0.3 µM
on cancer cells (Fig. 3A) is similar to the one of the NCI (GI50: 0.2 µM).
3.2. CM16 exerts in vitro anticancer activity through cytostatic effects
The cytostatic activity of CM16 was confirmed by means of
quantitative videomicroscopy in glioma Hs683, melanoma SKMEL-28
and MDAMB-231 breast cancer cells using the MTT-derived GI50
concentrations as illustrated morphologically and quantitatively
(Fig. 3B-C). We further investigated the cytostatic effects of CM16 at
its GI50 using flow cytometric cell cycle analysis but did not observe any
significant effect as previously shown (Fig. 1A-B in Carvalho et al.
(2017)). Thus, CM16-induced growth inhibition is not related to a
specific cell cycle phase or arrest. Accordingly, we observed that CM16
and its previously studied analogues (Frédérick et al., 2012) do not
interact with DNA when assayed in vitro (data not shown), as opposed
to harmine and related compounds that display DNA intercalating and
groove binding properties (Nafisi et al., 2010; Sarkar et al., 2014).
3.3. CM16 cellular penetration and distribution
Fluorescent properties of CM16 were used to study its cellular
penetration and distribution by fluorescence microscopy. CM16 ap-
peared to penetrate as early as 5 min after initiating treatment (Fig. 4A)
in the perinuclear region, while the nucleus itself remained unstained
even after 6 h of treatment (data not shown). Moreover CM16 appeared
to co-localize with the endoplasmic reticulum (Fig. 4B-D for Hs683,
SKMEL-28 and MDA-MB-231, respectively), where the translation
machinery is assembled. However, no obvious differences were re-
vealed in cell penetration or distribution of CM16 between non-
A. Carvalho et al. European Journal of Pharmacology 805 (2017) 25–35
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transformed fibroblasts and cancer cells that could explain, even partly,
the selectivity we observed above (data not shown).
3.4. CM16 inhibits protein synthesis
To evaluate whether CM16 could be a protein synthesis inhibitor,
its NCI GI50-based cellular sensitivity profile was compared to those of
> 765,000 compounds in the NCI database using the COMPARE
algorithm (Paull et al., 1989). Among 11 compounds, displaying a
COMPARE correlation coefficient (CCC) with CM16 above 0.7, me-
chanistic information was available for 8 (SCOPUS database as of
September 2016), of which 6 have been described as potential protein
synthesis inhibitors (Table 1). Moreover, significant correlation (CCC of
0.71) was found with 5a, one of the previously studied analogues of
CM16 (Table 1) (Frédérick et al., 2012). Consequently, we investigated
the effects of CM16 on newly synthesized proteins in transformed
Hs683, SKMEL-28 and MDAMB-231 and in NHDF non-transformed
cell lines (Fig. 5A-D). Hs683 and SKMEL-28 cells were treated with 0.5
and 5.0 µM of CM16 from 1 to 6 h, treatment schedules that induced
cytostatic effects only, as verified by videomicroscopy (Fig. 3C). At
5 µM, the neosynthesized protein level was decreased by 50% after only
a 1 h treatment in SKMEL-28 cells and 3 h in HS683 cells and the
inhibition was concentration-dependent. At 0.5 µM, the treatment
period had to be increased from 6 to 24 h to obtain a similar decrease
(data not shown). Similarly, we observed a concentration-dependent
decrease in incorporated 35S methionine in MDA-MB-231 breast
cancer cells after only 80 min of treatment with CM16, with the
concentration of 10 µM leading to nearly a complete inhibition of
protein synthesis (Fig. 5D). Evaluation of newly synthesized proteins in
NHDF normal fibroblast cells showed no significant different response
than cancer cell model (Fig. 5C and D). We also envisaged effects at the
transcription level but no alteration of the incorporation of a nucleotide
analog into the newly-transcribed mRNA for up to 24 h and in the
presence of up to 5.0 µM CM16 in Hs683 and SKMEL-28 cells lines
could be observed (Fig. 2A-B (Carvalho et al., 2017)). We concluded
that CM16 does not inhibit transcription while it does inhibit mRNA
translation, at least as a common feature across the different cellular
models used in the present study.
3.5. CM16 affects ribosomal organization in cancer cells
To investigate the effects of CM16 on translation further, we
evaluated the ribosomal assembly into 80S functional subunit and
polysome organization by means of sucrose gradients. CM16 induced
the accumulation of 80S ribosomes in treated cells, while polysomes
decreased after 80 min of treatment at 10 µM (the concentration that
completely inhibited 35S methionine incorporation in 80 min) in MDA-
MB-231 (Fig. 6A). We confirmed that ribosomal organization in Hs683
and SKMEL-28 cells was affected as early as after a 3 h treatment with
lower concentrations, i.e. 0.5 and 5.0 µM CM16 (Fig. 6B-C). Again, we
observed an accumulation of the fractions corresponding to the free
80S ribosome when compared to puromycin-induced effects (Fig. 6B).
Non-transformed fibroblasts also displayed similar altered profiles but
at high concentrations only (Fig. 6D-E).
Because actin plays critical roles in translation initiation and proper
polysome organization (Gross and Kinzy, 2007), fluorescent staining of
fibrillary actin was performed in the absence or presence of 0.5 and
5.0 µM of CM16 over a 24 h period but no significant modification was
noticed, at least in Hs683 and SKMEL-28 (data not shown).
3.6. Initiation factors are involved in CM16-induced inhibition of
mRNA translation
Because the previous chemical series were shown to modify the
eIF2α expression and activity levels (Frédérick et al., 2012), we further
investigated if CM16 could affect mRNA translation by eIF2α targeting.
Its phosphorylation was observed in MDA-MB-231 cells when treated
with 2.5 and 10 µM of CM16 for 80 min, an effect also found in NHDF
cells (Fig. 7A). To further evaluate whether the expression level of
eIF2α and its partners eIF2β and eIF2γ could drive, at least partly, the
sensitivity of cells to CM16, we utilized the NCI cell line transcriptomic
Table 1
Correlations of CM16 with protein synthesis inhibitors in the NCI 60-Cell-Line Screen using the COMPARE Algorithm.
Compound Correlation CM16 (NSC
779185)
Information References
NSC 656902 0.744 Quassinoid tested by NCI among other
quassionoids that were protein synthesis
inhibitors
Beutler et al. (2009)
PHYLLANTHOSIDE,S3′-DESACETYL – NSC
342443
0.723 Protein synthesis inhibitor (Phyllanthoside - NSC
328426)
Chan et al. (2004); Garreau de Loubresse et al.
(2014)
CHROMOMYCIN A3 – NSC 58514 0.722 1. Protein synthesis inhibitor 1. Chan et al. (2004); Hsu et al. (2012); Mir and
Dasgupta (2001)
2. NF-kappaB inhibitor +effect on estrogen
receptor
2. Miller et al. (2010)
3. Effect on TRAIL and Wnt signaling pathways 3. Toume et al. (2014)
MALFORMIN A – NSC 324646 0.713 1. Protein synthesis inhibitor (preventing IL-1
induced endothelial changes)
1. Bannon et al. (1994)
2. Effect on cell cycle 2. Hagimori et al. (2007)
3. Fibrinolytic activity 3. Koizumi et al. (2011)
4. Activity against cancerous cell lines 4. Dobretsov et al. (2016); Li et al. (2013);
Zhan et al. (2007)
5. Cytotoxic effect on cancerous cell lines 5. Liu et al. (2015)
6. Anti-Tobacco mosaic virus 6. Tan et al. (2015)
5a – NSC 760180 0.713 Protein synthesis inhibitor Frédérick et al. (2012)
BOUVARDIN – NSC 259968 0.707 Protein synthesis inhibitor Chitnis et al. (1981); Gladstone et al. (2012);
Stickel et al. (2015); Zalacaín et al. (1982)
Fig. 1. Chemical structure of the β-carboline derivative CM16.
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characterization.1 Indeed, although the GI50 values of CM16 in the
majority of the NCI cell line panel are close to the average of 0.2 µM
(Fig. 2A), and without large variation, four cell lines appeared poorly
sensitive to CM16 with GI50 > 1 µM (least sensitive, LS) while five
other appeared highly sensitive, i.e. those with a GI50 < 0.1 µM (most
sensitive, MS). We thus compared the transcriptomic expression levels
of eIF2α and its partners eIF2β and eIF2γ between these two groups of
cell lines displaying two orders of magnitude difference of sensitivity to
CM16 but no statistical significance could be observed (Fig. 7B).
Eukaryotic translation initiation factor 2 alpha kinase 3 (PERK) is a
key kinase regulating eIF2α phosphorylation (Ron, 2002) and thus
activity. However, CM16 did not alter PERK kinase activity in vitro as
shown in Fig. 3 in Carvalho et al. (2017). We then extended the
comparison of the highly versus poorly sensitive cell lines of the NCI to
a more extensive list of 57 components, actors and regulators of
translation (Table 1 in Carvalho et al. (2017)). Interestingly among
these 57 targets of the translation machinery selected, only three
initiation factors were found to be significantly differentially expressed
between the two groups: EIF1AX, EIF3E and EIF3H (Fig. 7C), while
neither elongation nor signaling pathways investigated were different
(data not shown). The expression level of initiation factors could thus
drive, at least partly, the sensitivity of a cell line to CM16 and further
support the effects of this compound on the initiation phase of
translation.
4. Discussion
Malignant cells require higher levels of protein synthesis to main-
tain several oncogenic programs (Silvera et al., 2010) and in recent
years it has been extensively shown that several distinct dysregulations
of the translation process occur in cancer cells (Nasr and Pelletier,
BA GI50: CM16 LC50: CM16
Fig. 2. In vitro anti-cancer effects of CM16 in the NCI 60-cell line panel. (Adapted presentation - shown with the permission of the NCI) A: Global growth inhibition [GI50] of each cell
line after 48 h of culture with CM16. “-7” represents the mean GI50 of the 60 cell lines, i.e. 0.2 µM. Log10 differences are represented by the bars. B: Lethal concentration [LC50] of CM16
for each cell line compared to the mean LC50 [“-5”]. The scale of the bars is in log10 as for A and B.
1 We did not perform proteomic comparison of these cell lines because some data were
missing for several targets and cell lines rendering the analysis impossible to interpret.
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2012; Ruggero, 2013; Spilka et al., 2013). Direct inhibitors of the
translation machinery, targeting the eIF4F, eIF3 or the ternary
complexes, are under investigation at different stages of development
(for a detailed review of therapeutic inhibitors of translation in cancer,
see (Bhat et al., 2015)). Efforts toward this goal also include the
development of inhibitors of upstream signaling pathways (e.g., PI3K-
mTOR and MNK) (Bhat et al., 2015; Blagden and Willis, 2011; Malina
et al., 2012). Our research aimed at the elucidation of the anti-cancer
potential of a preclinical candidate CM16, a β-carboline derived from a
harmala alkaloid harmine (Meinguet et al., 2015), which was investi-
gated herein as a protein synthesis inhibitor in vitro.
First, we observed that CM16 exerts cytostatic effects at its GI50
concentration in cancer cells (Figs. 2A and 3B-C) and that it displays at
least 10 times more selectivity in inhibiting the growth of cancer cells
as compared to non-cancerous cell lines (Fig. 3A). Although cytostatic,
CM16 did not induce any cell cycle phase arrest, which is consistent
with the lack of its interaction with DNA as well as the absence of CM16
localization to the nucleus (Fig. 4A).
We compared the growth inhibitory profile of CM16 in the 60 NCI
cancer cell line panel to those of the existing compounds in the NCI
database using the COMPARE software, which expresses and ranks the
similarities in the differential cellular sensitivities as the Pearson
correlation coefficient (Paull et al., 1989). This approach has been
successfully employed to identify new inhibitors of translation in the
past (Chan et al., 2004) and it indeed supported CM16 as a protein
synthesis inhibitor.
Further, the inhibition of translation induced by CM16 in different
cancer models, such as melanoma, glioma and breast cancer cell lines,
was found to be time- and concentration-dependent while no effect on
transcription was observed. These results are consistent with the
parallel intracellular distribution of CM16 with the endoplasmic
reticulum (Fig. 4B-D), the major site for mRNA translation (Reid and
Nicchitta, 2015). Importantly, because no selectivity against a cancer
type appeared in the NCI panel, we conducted the assays in cancer cell
models from different origins, i.e. glioma, melanoma and breast cancer
cell lines to avoid cell-type and context-dependent limitations. In fact,
CM16 appeared to affect translation initiation as illustrated by
ribosomal disorganization in the three cancer cell models used while
those effects were observed at higher doses only in the non-cancerous
models. Translation initiation is dependent on the formation of eIF4F
complex (eIF4G, eIF4A and eIF4E), which recruits the 40S ribosomal
unit, and the ternary complex (eIF2, tRNAmet and GTP), necessary for
initiation. Previous beta-carboline compound series was shown to
decrease eIF2α expression and/ or phosphorylation levels (Frédérick
et al., 2011). In this study, preliminary data obtained with breast
cancer cells indicate that CM16 could induce eIF2α phosphorylation
(Fig. 7A), which will in turn compromise the formation of the ternary
complex and binding of tRNAmet to the ribosome (Hinnebusch and
Lorsch, 2012), and thus inhibit protein synthesis (Koromilas, 2015).
Compared to harmine derivatives previously characterized, com-
pound CM16 is less hydrophobic and does not bear large substituents
like phenyl or cyclohexyl rings. At the present stage of our investiga-
tions, it is however difficult to link differences in eIF2α activity within











































































Fig. 3. CM16-induced cytostatic growth inhibition effects in cancer cells. A: Cell growth inhibition in cancer cells (solid line) versus non-cancerous cells (dashed line) treated
with CM16 for 72 h. Cancerous cell lines: Hs683, SKMEL-28 and MDA-MB-231. Non-cancerous cell lines: NHLF and NHDF non-transformed fibroblasts. Data are expressed as the
mean of viable cells relative to control (100%) ± S.E.M. of the six replicates of one representative experiment. B: Global growth ratio in HS683, SKMEL-28 and MDA-MB-231 cells after
24 h, 48 h and 72 h treatments with CM16 at their GI50. Results are expressed as the mean growth ratio between treated cells relative to control (1) ± S.E.M. of three replicates of one
representative experiment. C: Videomicroscopy of CM16-induced in vitro effects in Hs683, SKMEL-28 and MDA-MB-231. Figures are representative of one experiment performed in
three replicates.
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convincing (Q)SAR can be proposed. A family of four kinases –
eukaryotic translation initiation factor 2 alpha kinase 1 (HRI), eukar-
yotic translation initiation factor 2 alpha kinase 2 (PKR), eukaryotic
translation initiation factor 2 alpha kinase 4 (GCN2) and PERK –
regulates eIF2α phosphorylation (Koromilas, 2015; Ron, 2002; Wek
et al., 2006). While no direct effect of CM16 on PERK kinase activity in
vitro could be evidenced (see Fig. 3 in Carvalho et al. (2017)) it remains
possible that CM16 acts, at least partly, through ER stress-mediated
activation of PERK in cellular assay (Koromilas, 2015) and/or via the
other kinases mentioned above.
CM16 selectivity towards cancer cells was observed through the in
vitro evaluation of growth inhibition (Fig. 3A). We also observed that
CM16-induced ribosomal disorganization was present but less pro-
nounced in non-cancerous cell models (Fig. 6D-E). Interestingly,
targeting initiation proteins instead of elongation ones would offer
greater selectivity in inhibiting the growth of cancer cells as elongation
inhibitors seem to have a narrow therapeutic window due to the
inhibition of global protein synthesis of non-transformed cells
(Lindqvist et al., 2009; Malina et al., 2012). Moreover, several
initiation proteins are dysregulated in cancer cells as compared to
normal cells. As CM16 induces phosphorylation of eIF2-α similarly in
cancerous and non-cancerous cells (Fig. 7A), it is unlikely that the
effects on this initiation factor are responsible for the selectivity
observed. Also, no difference in cell penetration and distribution of
CM16 between non-cancerous and cancerous models could be found to
explain this selectivity. Therefore, we extended the study to 57 genes
involved in translation initiation and elongation or in their control
using the transcriptomic characterization of the NCI 60 cell line panel.
Among these 57 targets (see Table 1 in Carvalho et al. (2017)), the
mRNA levels of only three initiation factors, i.e. EIF1AX, EIF3E and
EIF3H, were found to be significantly different in highly sensitive
cancer cell lines compared to those with low sensitivity towards CM16
(Fig. 7C). eIF1A, the protein encoded by EIF1AX, is important in the
formation of the pre-initiation complex, composed of the 40S subunit,
eukaryotic translation initiation factor 1 (eIF1), eukaryotic translation
initiation factor 5 (eIF5), eIF3 and the ternary complex (Bhat et al.,
2015; Spilka et al., 2013), and together with eIF1, is required for
mRNA scanning and binding at the initiation codon (Spilka et al.,
2013). Mutations in the EIF1AX gene have been associated with tumor
development and progression in thyroid cancer (Jung et al., 2016;
Landa et al., 2016) uveal melanomas (Decatur et al., 2016; Field et al.,
2016) and possibly ovarian tumor carcinogenesis (Hunter et al., 2015).
Knowledge of its functional roles in cancer biology is still currently
limited (Spilka et al., 2013) and warrant further investigations.
Similarly, eIF3e and eIF3h have been both reported to be dysregulated
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Fig. 4. CM16 cellular penetration and distribution in the ER and protein synthesis inhibition A: CM16 fluorescence properties allow its visualization in blue color (filter
ex/em: 359–371/397 nm) in Hs683 cells over time after 5 µM treatment. B: CM16 parallel distribution to the endoplasmic reticulum fluorescent probe (ER-tracker) after a 3 h
treatment in Hs683, C: SKMEL-28 andD: MDA-MB-231 cell lines. Exposure times for blue filter (ex/em) 359–371/397 nm: 40 ms (SKMEL-28) and 80 ms (Hs683 and MDA-MB-231);
and for red filter (ex/em) 540–580/593–668 nm: 283 ms (SKMEL-28) and 850 ms (Hs683 and MDA-MB-231). All pictures were taken with a 40x objective. Illustrations are
representative of one experiment performed in two replicates.




















































































Fig. 5. Analysis of the newly synthesized proteins in A: Hs683 and, B: SKMEL-28 and C: NHDF cells by fluorescent assay. Positive control: cycloheximide 0.1 mM for 1 h. Data
are expressed as the mean neosynthezised protein amounts normalized to the control (100%) ± S.E.M. of the six replicates of one representative experiment. D: Dose-dependent






























































Fig. 6. CM16 effects on ribosomal organization by sucrose gradient analysis. Effect of CM16 on ribosomal units and polysome organization after treatment. A:MDA-MB-231
cells incubated for 80 min with CM16 at 10 µM in comparison to the control. B: Cancerous cell lines Hs683 and C: SKMEL-28 and non-cancerous cell lines D: NHDF and E: NHLF
incubated with CM16 at 0.5 µM or 5.0 µM for 3 h (grey lines) in comparison to the control (solid black line). Puromycin was used as positive control (1 h, 184 µM) to visualize the 80S
peak containing fractions. Three or one independent experiments were performed, depending on the cell line. Each profile is representative of one experiment.
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Fig. 7. Initiation factors study. A: Effects of CM16 on the expression and phosphorylation status of eIF2α in MDA-MB231 cancerous and NHDF non-cancerous cells by western
blot. Representative western blot of two experiments. B and C: Comparison of the transcriptomic expression levels of main translation initiation genes in the most (MS) versus least
sensitive (LS) cell lines to CM16 effects among the NCI-cell-line-panel screening. The four least sensitive cell lines (i.e. those with a GI50 > 1 µM) are HCT-15 [−5.72], NCI/ADR-RES
[−5.36], Caki-1 [−5.85] and UO-31 [−5.80]. The five most sensitive cell lines (i.e. with a GI50 < 0.1 µM) are A498 [−8.00], HL60 [−7.30], CCRF-CEM [−7.12], RPMI-8226 [−7.19] and
T47D [−7.23]. B: Transcriptomic comparison of eIF2α, β and γ subunits between the most and least sensitive cell lines to the CM16 growth inhibitory effects identified in the NCI cell
line panel. C: Transcriptomic comparison of the targets with significantly different expression levels between the cell lines most and least sensitive to CM16 growth inhibitory effects
identified in the NCI cell line panel by means of t-test comparison. Increased expression levels as compared to the 60 cell line mean appear in black while decreased expression levels
appear in grey. Results are expressed as Z scores as provided by the NCI database. Z scores are determined for each probe/cell line pair by the subtraction from its intensity of the probe
mean (across the 60 cell lines), and division by the standard deviation of the probe (across the 60 cell lines). The z score average was then calculated as the mean across all probes and
probe sets that passed quality control criteria.
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complex, i.e. the eIF3 complex, which is composed of 10–13 subunits
acting together in the initiation process. Their main roles include
recruitment of the mRNA to the 40S ribosomal unit and stabilizing the
ternary complex (Bhat et al., 2015; Spilka et al., 2013). At the protein
level, eIF3e affects proliferation and survival of glioblastoma cells
(Sesen et al., 2014), is involved in colon tumor progression (Li et al.,
2014) and breast tumor formation, (Suo et al., 2015) progression
(Grzmil et al., 2010) and metastasis (Gillis and Lewis, 2013). High
levels of eIF3h maintain the malignancy of several cancer cell lines in
vitro (Zhang et al., 2008) and have been indeed observed in breast,
prostate and hepatocellular carcinomas (Hershey, 2015; Zhu et al.,
2016). How the targeting of these initiation factors help to explain
superior activity of CM16 against cancerous over non-cancerous cells
remains to be investigated.
5. Conclusion
Translation inhibition in cancer is emerging as a new and promising
alternative to the existing therapies due to the specific alterations of the
translation machinery in cancer cells. The results of the present
investigation show that CM16, a preclinical candidate derived from a
harmala alkaloid harmine with favorable drug-like physico-chemical
characteristics, inhibits cancer cell protein synthesis at the mRNA
translation level via perturbation of their ribosomal organization.
EIF1AX and EIF3 complex members, recently reported to be involved
in cancer onset and progression, were found in the present study to be
differentially expressed in cancer cell lines depending on their sensi-
tivity towards CM16.
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